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Abstract 
Background: Epstein–Barr virus-positive mucocutaneous ulcer (EBVMCU) is a recently recognized B cell lymphopro-
liferative disorder that is driven by latent EBV infection and causes discrete ulcerations in the oropharynx, gastroin-
testinal tract, and skin. Local attenuation of immunosurveillance associated with iatrogenic immunosuppressant use, 
primary immunodeficiency, or age-associated immunosenescence has been implicated as a predisposing factor. This 
disorder is likely under reported, as it was only first defined in 2010 and shares histological features with other B-cell 
proliferative neoplasms. The first case series that described EBVMCU suggested that EBVMCU is generally self-limited 
and is likely to resolve without treatment. Since that publication, additional cases have been reported that describe a 
more heterogeneous clinical course, often requiring aggressive therapy. We now systematically review all published 
cases of EBVMCU and detail a case of aggressive and progressive EBVMCU, including diagnostic and management 
challenges, as well as successful treatment with radiation therapy.
Case presentation: A forty-nine year old woman presented with painful and debilitating multifocal oral EBVMCU 
that initially responded to four weekly doses of rituximab. Her disease relapsed within 3 months and continued to 
progress and cause significant morbidity. She was successfully treated with local external beam radiation therapy of 
30 Gy in 15 fractions, with duration of response of at least 6 months.
Conclusions: We suggest that although many patients with EBVMCU experience a self-limited course, for others 
EBVMCU can be a debilitating, persistent disorder that requires aggressive therapy to prevent disease progression. 
CD20- and CD30-directed antibody therapy, local radiation therapy, local surgical excision, systemic chemotherapy, 
and a combination of these therapies have all been successfully used to treat EBVMCU with high rates of durable 
clinical remission. As EBVMCU is not currently included in the 2008 WHO classification of lymphoproliferative disorders 
and no evidence-based guidelines or expert opinions have been proposed to guide therapy, this case report and 
systematic review provides a foundation on which to guide therapeutic decisions.
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Background
EBV biology
Epstein–Barr virus (EBV), also known as human herpes 
virus 4, is one of eight viruses within the human herpes 
virus family that infects humans and is directly trans-
ferred between humans through saliva [1]. EBV prefer-
entially infects B-cells through binding of viral envelope 
glycoprotein gp350/220 to CD21 (complement receptor 
type 2) on B-cells [2]. This binding facilitates the inter-
action of viral glycoprotein gp42 with B-cell major histo-
compatibility complex (MHC) class II, thereby triggering 
fusion of the viral envelope with the B-cell plasma mem-
brane and allowing EBV deoxyribonucleic acid (DNA) 
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entry into the B-cell [3]. Although a primary lytic infec-
tion may result, more often viral latency is established 
when the 172 kilobase linear, double stranded viral DNA 
circularizes within the cell and persists as an episome in 
the nucleus of an infected B-cell [4].
During latency, multiple EBV-encoded ribonucleic 
acids (RNAs) and proteins may be transcribed and 
expressed that promote lymphocyte proliferation and 
survival and maintain viral latency [5]. Newly infected 
naïve B-cells may express all of the EBV latency genes 
and exist in a highly immunogenic state referred to as 
latency III [5]. After initial proliferation, some EBV-
infected naïve B-cells undergo germinal center reactions 
that increase the clonal expansion and cellular pool of 
EBV-infected B-cells [6]. Germinal center B-cells tran-
scribe a more limited set of EBV genes, referred to as 
latency II [5]. When germinal center B-cells differenti-
ate into long lived, resting memory B-cells, a long-term 
reservoir of EBV infection is established [7] with minimal 
transcription of viral genes (latency I) [5]. The absence 
of MHC presentation of viral antigens facilitates viral 
latency by promoting escape from immunosurveillance. 
If a resting memory B-cell is activated, it may differenti-
ate into a plasma cell and induce the EBV lytic life cycle 
and production of new EBV virions capable of infecting 
additional B-cells and propagating viral latency indefi-
nitely. B-cell transformation into malignant cells can 
occur in latently EBV-infected B-cells, with constitu-
tional activation of nuclear factor-κB [8] and apopto-
sis suppression [9] by viral RNAs and proteins at least 
partially implicated. Immunosuppression from human 
immunodeficiency virus (HIV), chemotherapeutics, 
or immunosuppressive agents as well as age-related 
immunosenescence may facilitate EBV-associated B-cell 
transformation by reducing T-cell mediated immunosur-
veillance and enabling expansion and proliferation of the 
EBV-infected B-cell reservoir.
EBV lymphoproliferative disease spectrum
Most individuals are exposed to EBV during the first 
several decades of life and experience an asymptomatic 
infection or a self-limited lymphoproliferative infec-
tive mononucleosis [10, 11]. Viral latency and long-
term persistence are established in the memory B-cell 
compartment after initial infection [7]. In some indi-
viduals EBV may potentiate B-cell transformation and 
cause a spectrum of EBV-associated lymphoprolifera-
tive disorders including Burkitt lymphoma [12], classi-
cal Hodgkin lymphoma [13], plasmablastic lymphoma 
[14], primary effusion lymphoma [15], diffuse large 
B-cell lymphoma associated with chronic inflamma-
tion [16], EBV-positive diffuse large B-cell lymphoma 
of the elderly [17], lymphomatoid granulomatosis [18], 
post-transplant lymphoproliferative disorder (PTLD) 
[19], and EBV-positive mucocutaneous ulcer disease 
[20]. In addition, T-cells and natural killer (NK) cells can 
be influenced by surrounding EBV-infected B-cells and 
can be directly infected with EBV [21, 22] resulting in 
rare EBV-associated T-cell lymphoproliferative disorders 
including peripheral T-cell lymphoma [23, 24], angio-
immunoblastic T-cell lymphoma [25], extranodal nasal 
type NK/T-cell lymphoma [26], enteropathy-associated 
T-cell lymphoma [27, 28], gamma-delta T-cell lymphoma 
(hepatosplenic and nonhepatosplenic) [29, 30], systemic 
EBV-positive T-cell lymphoproliferative disease of child-
hood [31], EBV-associated anaplastic large cell lym-
phoma [32], and aggressive NK-cell leukemia [33].
EBV‑Positive mucocutaneous ulcer
EBV-positive mucocutaneous ulcer (EBVMCU) was 
first described and proposed as a distinct clinical entity 
in 2010 by Dr. Elaine Jaffe’s group at the National Can-
cer Institute [20]. They described 26 cases in which 
patients exhibited a common clinical presentation of 
mucocutaneous ulcers that had a unique histology and 
immunophenotype among EBV-associated lymphopro-
liferative disorders (Table  1). EBVMCU was described 
as shallow, sharply circumscribed mucosal or cutaneous 
ulcers with an underlying polymorphous infiltration of 
small lymphocytes, immunoblasts, and atypical larger 
lymphocytes, and with a variable admixture of scattered 
plasma cells, eosinophils, and histiocytes. A promi-
nent rim of small T-lymphocytes was also noted at the 
base of the lesions. The atypical lymphocytes were large 
and pleomorphic immunoblasts with frequent Hodg-
kin and Reed-Sternberg (HRS) morphology. Variably 
sized plasmacytoid apoptotic cells were often seen and 
angioinvasion and tissue necrosis were variably present. 
The immunoblasts had a B-cell immunophenotype with 
uniform expression of CD30, MUM1, PAX5, and OCT-
2, and variable CD20, CD45, CD15, CD79a, and BCL-6 
expression. EBV was present in the infiltrating small 
B-cells, plasmacytoid apoptotic cells, and immunoblasts, 
as demonstrated by EBER-positive in  situ hybridiza-
tion and LMP1 colocalization, suggesting type II latency. 
Monoclonal immunoglobulin rearrangement was iden-
tified in a subset of cases (38.9  %), indicating a clonal 
EBV-driven B-cell proliferation. Monoclonal or clonally 
restricted T-cells were also identified in 69 % of the cases, 
consistent with a restricted T-cell repertoire against 
EBV-epitopes.
Since the first description of EBVMCU in 2010, 25 
additional cases have been reported (Table 2). In addition, 
several cases of isolated mucocutaneous ulcers in the set-
ting of immunosuppression were published prior to 2010 
and may in fact represent cases of EBVMCU, although 
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thorough pathologic findings were not reported [34–41]. 
In all 51 published cases, EBV-associated mucocutaneous 
ulcers were noted to occur in the oropharynx, gastroin-
testinal tract (GI), or cutaneous skin. The oropharynx 
was the most common site affected in these cases (41 %), 
likely because the oropharynx is the most frequent por-
tal of entry for EBV and site of primary infection [1, 42], 
often within Waldeyer’s ring [43, 44]. Most patients had 
solitary lesions; however 16  % of patients developed 
multifocal disease. One of the 51 patients had evidence 
of active EBV viremia [45], while the remainder of indi-
viduals were immunosuppressed either secondary to 
iatrogenic immunosuppressive agents (methotrexate, 
azathioprine, cyclosporine, mycophenolate, or tacroli-
mus) in 56  %, underlying immunodeficiency syndrome 
(hypogammaglobulinemia, T-cell deficiency) in 4  %, 
or presumed immunosenescence from advanced age 
(median age 80 years, range 64–101 years) in 40 %. Inter-
estingly, most of the patients with iatrogenic immuno-
suppression from immunosuppressive agents were also 
of advanced age (median 63 years, mode 80 years, range 
18–81  years), suggesting that immunosenescence may 
be a predisposing factor to development of EBVMCU in 
individuals receiving therapeutic immunosuppression. 
Both immunosuppression (primary and acquired) and 
immunosenescence are thought to diminish the EBV-
responsive T-cell repertoire and reduce the ability of 
T-cells to recognize the full range of EBV epitopes [46]. 
In particular, during immunosenescence, clonal CD8-
positive T-cells with a mature memory cell phenotype 
and reduced functionality accumulate as a result of an 
age-related diminished capacity to generate new naïve 
T-cells [46, 47]. As a result, oligoclonal T-cell populations 
with restricted epitope specificity accumulate and reduce 
the efficacy of immunosurveillance [48, 49]. In this set-
ting, EBV-driven clonal proliferation of lymphocytes and 
subsequent transformation to a malignant phenotype 
may be facilitated. Certain immunosuppressants may 
additionally promote EBV-directed lymphocyte prolif-
eration. For example, methotrexate directly activates EBV 
early promoters resulting in activation of EBV replication 
[50] while cyclosporine-A induces oxidative stress that in 
turn directly activates EBV [51]. As a result, lymphopro-
liferation may be preferentially driven at sites where 
latently infected EBV lymphocytes are more prevalent.
EBVMCU management and unanswered questions
The first case series in which EBVMCU was described 
suggested that EBVMCU is a relatively benign condi-
tion with a self-limited disease course that generally 
does not require treatment. Our institutional experi-
ence and a review of all published cases suggest that 
for some, EBVMCU can be a progressive and debili-
tating condition that requires aggressive therapy. As 
the Word Health Organization (WHO) has not for-
mally recognized EBVMCU as a unique clinical entity, 
there are no guidelines or consensus opinions to guide 
treatment. Therefore, we describe a case of progres-
sive EBVMCU that required aggressive therapy and 
comprehensively review all other published cases to 
provide a framework on which to base management 
decisions.
Table 1 Pathologic Features of EBVMCU
Histology Immunophenotype
Shallow, sharply circumscribed ulcers Immunoblasts often with HRS features:
 strong positivity for CD10, CD30, MUM1
 uniform positivity for PAX5 and OCT-2
 variable expression of CD20, CD45, CD15, CD79a, BCL-6, BOB.1
Localized to mucosa of oropharynx and gastrointestinal tract or to skin Infiltrating lymphocytes:
 CD4 and CD8 positivity
Polymorphous infiltrate of lymphocytes and immunoblasts Clonality
Variable admixture of scattered plasma cells, eosinophils, and histiocytes Immunoblasts with HRS features:
 monoclonal immunoglobulin rearrangement
Medium sized lymphocytes with angulated nuclei Infiltrating T-lymphocytes:
 frequent monoclonal or restricted TCR pattern
Pleomorphic immunoblasts with frequent Hodgkin and Reed-Sternberg  
(HRS) morphology
Association with EBV
Plasmacytoid apoptotic cells Immunoblasts and HRS cells:
 uniformly EBER1-positive
Variable angioinvasion Infiltrating T-lymphocytes:
 frequently EBER1-positive
Variable tissue necrosis Plasmacytoid apoptotic cells:
 uniformly EBER1-postive
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Table 2 Summary of Reported Cases of EBVMCU disease




53 F Colon, rectum Methotrexate + infliximab (CD) Reduced IS PD→HL [75]
56 F Skin (leg) Methotrexate (PM) Reduced IS CR (33 m) [76]
59 F Eyelid Methotrexate (RA) Reduced IS CR (37 mo) [76]
60 F Lip mucosa Methotrexate (RA) Reduced IS CR (72 mo) [20]b
61 F Skin (leg) Methotrexate (RA) R-CHOP CR (25 mo) [76]
62 F Lip, nose, eyelid Methotrexate (PM) Reduced IS CR (1 mo) [45]
64 F Buccal mucosa Methotrexate (RA) Reduced IS Dieda [76]
65 M Palate Methotrexate (RA) Reduced IS CR (19 mo) [77]
69 F Colon Methotrexate (RA) NR NR [20]b
76 F Eyelid Methotrexate (RA) Reduced IS CR (24 mo) [76]
80 M Tongue base Methotrexate (RA) NR NR [20]b
80 F Skin (arm) Methotrexate (RA) Reduced IS CR (60 mo) [20]b
81 F Tongue Methotrexate (RA) Reduced IS CR (12 mo) [78]
42 M Oral mucosa Azathioprine (sarcoidosis + MG) NR NR [20]b
63 M Skin (perianal) Azathioprine (CD) Reduced IS CR (6 weeks) [79]
75 F Esophagus Azathioprine (RA) Reduced IS CR (17 mo) [20]b
76 F Buccal mucosa Azathioprine (Pemphigoid) Reduced IS CR (13 mo) [80]
81 F Colon Azathioprine (ITP) None PD on diagnosis [81]
48 F Tongue Cyclosporine-A (SLE) Reduced IS CR (24 mo) [20]b
64 F Colon Cyclosporine-A (HSCT) Reduced IS CR (6 mo) [20]b
70 M Lip Cyclosporine-A, prednisone (renal 
transplant)
Reduced IS, surgical excision CR (111 mo) [82]
80 F Rectum Cyclosporine-A (UC) Reduced IS CR (23 mo) [20]b
63 F Gingiva Cyclosporine-A, prednisone,  
MMF (renal transplant)
Reduced IS CR (8 mo) [82]
44 M Tongue MMF, pred (renal transplant) Reduced IS CR (15 mo) [82]
45 M Gingiva MMF (SLE) NR NR [83]
61 M Esophagus MMF, pred (renal transplant) Reduced IS CR (16 mo) [82]
70 M Rectum MMF, pred (renal transplant) Reduced IS, rituximab (2 doses)  
velcade
CR (17 mo) [82]
18 M Tonsil, buccal mucosa MMF, prednisone, tacrolimus  
(cardiac transplant)
Reduced IS, rituximab (2 doses) CR (14 mo) [82]
32 M Terminal ileum MMF, prednisone, tacrolimus  
(bilateral lung transplant)
Reduced IS, rituximab (4 doses) CR (60 mo) [82]
Primary Immunodeficiency-Associated EBVMCU
45 F Gingiva T-cell deficiency NOS rituximab (8 doses) CR (24 mo) [62]
61 F Esophagus (multifocal) hypogammaglobulinemia rituximab (4 doses), IVIG (monthly), 
brentuximab (3 cycles)
PD [63]
EBVMCU of Unclear Etiology
49 F Gingiva, palate etiology not established rituximab (4 doses × 2) RT PD CR (6 mo) This case
EBVMCU secondary to age-associated immunosenescence
63 F Tonsil Age NR NR [20]
64 F Tongue, oral mucosa Age RT CR (15 mo) [20]b
68 F Tongue Age None SR (36 mo) [20]b
68 F Tonsil Age R-CHOP, RT CR (24 mo) [20]b
73 M Tonsil, tongue Age None RR (12 mo) [20]b
74 M Skin (neck) Age R-CHOP CR (24 mo) [84]
75 F Skin (arm) Age NR NR [20]b
76 M Tongue base Age None SR (12 mo) [20]b
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Case presentation
Initial presentation
A forty-nine year old homeless woman with a 35 pack 
year cigarette smoking history and no significant medical 
problems presented to primary medical care with com-
plaints of painful oral ulcerations on her gums and palate 
that had been present for at least 6 months. Her review 
of systems was unremarkable including an absence of 
constitutional symptoms, infectious symptoms, rheu-
matologic symptoms, lymphadenopathy, or history of 
recurrent infections, as well as a lack of history of or risk 
factors for HIV or immunosuppression. Her physical 
exam was notable for hypertrophic gums, a 1 cm ulcera-
tion adjacent to the right upper incisor, and a palatal 
ulceration near the left upper molars. She did not have 
palpable adenopathy, hepatosplenomegaly, rashes, joint 
tenderness, or joint effusions. Her differential diagno-
sis at time of presentation included trauma (necrotizing 
sialometaplasia), infection (herpes simplex virus/HSV, 
coxsackie virus, human immunodeficiency virus/HIV, 
syphilis, tuberculosis), autoimmune (systemic lupus ery-
thematosus, Behçet syndrome, reactive arthritis, Crohn 
disease orofacial granulomatosis variant, Sweet syn-
drome, granulomatosis with polyangiitis, mucous mem-
brane pemphigoid), carcinoma (squamous cell, malignant 
salivary gland tumor), or hematologic malignancy (B-cell 
lymphoma, T-cell leukemia/lymphoma).
Evaluation
Diagnostic studies included a normal complete 
blood count and differential with exception of a mild 
lymphopenia at 950  cells/μL, normal basic metabolic 
panel, normal liver function test and lactate dehydroge-
nase, negative autoimmune screen (antinuclear antibody, 
anti-neutrophil cytoplasmic antibodies), and negative 
serologies for HIV and viral hepatitis. Her EBV screen 
by polymerase chain reaction (PCR) of serum was also 
negative. Computed tomography (CT) of neck, chest, 
abdomen, and pelvis demonstrated bilateral diffuse lym-
phadenopathy in the neck with the largest lymph node 
measuring 2.4  cm (Fig.  1), but no adenopathy in the 
hilum, mediastinum, axilla, abdomen, retroperitoneum, 
pelvis, or inguinal region. The spleen size was normal at 
9.2 cm and the abdominal viscera appeared radiographi-
cally normal. The patient was referred to oral surgery for 
biopsy of her right maxillary perimolar lesion and left pal-
atal lesion. Pathologic findings are demonstrated in Fig. 2 
and Table 1. Extensive mucosal ulceration was noted with 
an underlying dense infiltration of small lymphocytes 
and frequent admixed large atypical lymphocytes includ-
ing rare Hodgkin and Reed-Sternberg (HRS)-like forms 
that were positive for CD30 (strong), PAX5 (uniform), 
CD20 (variable), EBER (uniform), and negative for CD3, 
CD15, and CD79a. Molecular studies demonstrated a 
clonal immunoglobulin gene rearrangement. The over-
all findings were consistent with a clonal EBV-driven, 
B-cell lymphoproliferative disorder. The diagnostic con-
siderations included EBV-positive mucocutaneous ulcer 
(EBVMCU) and other EBV-positive B-cell lymphomas 
including EBV-positive diffuse large B-cell lymphoma, 
however the patient declined excisional biopsy of cervical 
lymph nodes and bone marrow biopsy.
F female, M male, Ref reference, CD Crohn’s disease, RA rheumatoid arthritis, PM polymyositis, MG myasthenia gravis, ITP immune thrombocytopenia, SLE systemic 
lupus erythematosus, HSCT hematopoietic stem cell transplant, SOT solid organ transplant, UC ulcerative colitis, HL Hodgkin lymphoma, NOS not otherwise stated, 
Pred prednisone, MMF mycophenolate, IS immunosuppression, R-CHOP rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone, RT radiotherapy, IVIG 
intravenous immunoglobulin, PD persistent disease, CR complete response, NR not reported, SR spontaneous regression, RR relapsing remitting, Mo months
a Died soon after diagnosis from myelitis and sepsis
b Cases are also included in a second published series of EBV-associated lymphoproliferative disorders [87]
Table 2 continued
Age Sex Ulcer location Predisposing factor Treatment Response  
(durability)
Ref
79 M Skin (cheek) Age None SR (25 mo) [20]b
80 F Palate Age RT CR (60 mo) [20]b
81 F Palate Age None SR (14 mo) [85]
82 F Lip Age None RR (NR) [20]b
82 M Lip Age None SR (NR) [20]b
84 F Tongue, floor of mouth Age None SD (5 mo) [20]b
85 F Tonsil Age RT CR (3 mo) [20]b
88 F Tongue base Age None RR (24 mo) [20]b
88 M Skin (chest) Age None SR (3 mo) [20]b
89 M Tongue base Age NR NR [20]b
89 M Lip, skin (scalp) Age resection NR [86]
101 M Tonsil Age R-CHOP CR (12 mo) [20]b
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Disease course and management
Given CD20 expression on the large atypical lympho-
cytes, the patient received four weekly doses of rituximab 
(375 mg/m2) with immediate improvement of symptoms 
and ulcer regression. Unfortunately this response was 
short-lived. Within 3  months of completion of rituxi-
mab therapy the oral ulcers recrudesced and she declined 
additional diagnostic studies. Over the next 15  months 
the oral ulcers increased in extent, with multiple 
maxillary teeth spontaneously loss, increasing pain, and 
difficulty opening her mouth resulting in an inability to 
tolerate solid food, a 36-kilogram unintentional weight 
loss, and aspiration pneumonia and sepsis.
Repeat CT (Fig.  3) demonstrated irregular enhancing 
soft tissue deep to the left nasolabial region and ante-
rior premaxilla, encroaching on the left nasal vestibule. 
The tumor invaded the left maxilla. There was diffuse 
enhancement around the maxilla, palate, and upper oral 
mucosa. There were shotty bilateral cervical lymph nodes 
and small subcentimeter bilateral retropharyngeal nodes, 
but none clearly pathologic. On clinical exam, there was 
obvious left facial swelling along the left medial cheek 
and premaxillary region extending into the lip (Fig.  4a). 
She had limited oral opening due to pain. An ulcerative 
indurated mass was visible eroding the left maxilla and 
palate (Fig. 4b, c). It extended to the hard palate-soft pal-
ate junction with normal appearing soft palate mucosa. 
There was fullness and induration suggestive of submu-
cosal extension to the sublabial region and to the buccal 
mucosa from the lip commisure back to the retromolar 
trigone. A second ulcer was apparent on the right upper 
inner gum line extending from the incisors to molars 
(Fig. 4d) with gum hypertrophy (Fig. 4e) and induration 
of the right buccal mucosa extending about halfway back. 
The oral tongue appeared normal. A swab of her ulcers 
was negative for HSV by PCR and her screen for HIV and 
EBV was again negative by PCR of peripheral blood. She 
continued to be resistant to repeat biopsy and bone mar-
row evaluation. Given the brief response to prior rituxi-
mab therapy, four weekly infusions of rituximab dosed 
at 375  mg/m2 were administered; however, the patient 
failed to experience treatment response. Her oral ulcers 
persisted and increased in size resulting in an almost 
Fig. 1 CT of neck demonstrating bilateral diffuse lymphadenopathy 
with the largest lymph node measuring 2.4 cm (arrow)
Fig. 2 Biopsy of right incisural ulcer and left palatal perimolar ulcer. Hematoxylin and eosin (H&E) stain demonstrating scattered large atypical 
lymphocytes with occasional Hodgkin Reed-Sternberg (HRS) morphology in a background of mixed inflammatory infiltrate. These large atypical 
cells are positive for CD30
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total inability to tolerate oral intake with subsequent 
worsening weight loss, lethargy, and weakness.
Her large left palatal ulcer was biopsied with over-
all pathologic findings similar to that seen in her initial 
biopsy. Again noted was ulcerated mucosa with underly-
ing dense inflammatory infiltrate of small lymphocytes, 
eosinophils, neutrophils, histiocytes, and scattered large 
atypical lymphocytes with rare HRS-like forms. Sheets 
of large cells were not seen. Large atypical lympho-
cytes were uniformly positive for CD30, PAX5, MUM1, 
EBER, EBV LMP (Fig.  5), and negative for CD3, CD10, 
and CD20 (in the setting of recent rituximab exposure). 
The Ki-67 proliferation rate of the atypical lymphocytes 
was 70–80  %. Given the absence of lymphadenopathy 
or other systemic involvement of disease, a diagnosis of 
EBVMCU was rendered.
Although HIV testing had been repeatedly nega-
tive and the patient had no prior history of recurrent 
infections or exposure to immunosuppressive agents, a 
potential underlying immunodeficiency syndrome was 
considered. Quantitative immunoglobulin (Ig) and T-cell 
subset analysis was performed and her IgG and IgM 
were found to be mildly depressed at 544 mg/dL (refer-
ence range 620–1490  mg/dL) and 29  mg/dL (reference 
range 40–350  mg/dL), respectively, while her IgA was 
normal at 122  mg/dL (reference range 65–420  mg/dL). 
Her mild hypogammaglobulinemia was likely secondary 
to recent rituximab exposure, although pre-treatment 
quantitative immunoglobulins had not been evaluated. 
Interestingly her CD4 and CD8 T-cell counts were both 
depressed with an absolute CD4 T-lymphocyte count of 
125 cells/μL (reference range 733–2250 cells/μL) and an 
absolute CD8 T-lymphocyte count of 168  cells/μL (ref-
erence range 250–1240  cells/μL). Her CD4/CD8 ratio 
was relatively preserved at 0.73. Rituximab can cause 
B-lymphocyte depletion and subsequent hypogamma-
globulinemia [52], however it is generally not observed to 
cause either primary of secondary T-cell depletion [53]. 
Unfortunately T-cell subset analysis was not performed 
in our patient prior to rituximab exposure, and we were 
unable to determine whether she had an underlying 
immunodeficiency.
Given our patient’s poor response to recent systemic 
therapy, radiotherapy was considered as a therapeutic 
option given case report of excellent clinical response 
to radiation [20]. Details of radiotherapy including dose 
were not described; however, extrapolating from radia-
tion approaches with other lymphoproliferative condi-
tions such as low grade lymphomas, we expected doses 
in the range of 20–45  Gy in conventional fractionation 
(1.8–2  Gy per fraction) to be associated with a high 
rate of clinical response and local control with a favora-
ble toxicity profile. Regional nodal dissemination is not 
characteristic of EBVMCU, so elective nodal irradiation 
was not deemed necessary. Our patient received external 
beam radiation therapy using a three-dimensional con-
formal plan and a three-field approach (opposed lateral 
and anteroposterior fields; Fig.  6). The gross disease in 
the oral cavity was treated to 30 Gy in 15 fractions. She 
experienced a very brisk and complete clinical response 
with resolution of all oral ulcers and gum hypertrophy 
(Fig. 7) durable to 6 months.
Conclusions
Discussion
EBVMCU is a rare disorder, only recently recognized in 
2010 as a unique clinical entity, with 51 total reported 
cases in addition to this case, and no clear management 
guidelines to inform care. Although EBVMCU has not 
been included in the 2008 WHO classification schema of 
B-cell neoplasms, the presence of discrete ulcer(s) with 
an underlying polymorphous infiltrate of small lympho-
cytes, immunoblasts with frequent HRS morphology, 
plasma cells, eosinophils, and histiocytes is characteristic 
of the disorder. The immunoblasts are uniformly posi-
tive for EBER, CD30, PAX5, OCT-2, and MUM1; have 
variable expression of CD20, CD45, CD15, CD79a, and 
BCL-6; and demonstrate monoclonality in a subset. The 
incidence of EBVMCU is likely under recognized as some 
lesions may spontaneously regress without pathology 
being obtained, while other lesions may be misclassified 
Fig. 3 CT of neck demonstrating prominent maxillary gingival and 
palatal swelling and ulcerations with significant loss of maxillary teeth 
on the left side
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as methotrexate-associated ulcer, Hodgkin lymphoma, or 
diffuse large B-cell lymphoma, given the presence of large 
atypical lymphocytes with occasional HRS morphology 
and immunophenotype.
EBVMCU generally occurs as a solitary lesion but has 
been reported to be multifocal in 17  % of documented 
cases including the case we now report. The primary 
location of EBVMCU is the oropharynx (52 %), with skin 
(29 %) and GI tract (19 %) occurring less frequently. The 
recurrent localization of EBVMCU to the oral cavity and 
GI tract likely reflects the initial site of EBV inoculation 
in the oropharynx and persistence of latent EBV within 
lymphocytes of Waldeyer’s ring [44] and gut-associated 
lymphoid tissue [54]. EBV also has tropism for epithe-
lial cells [55, 56], and 60  % of skin-localized EBVMCU 
occur on the face at sites overlying the oropharynx. This 
implicates skin as a sanctuary site for latent EBV and a 
site of potential EBVMCU formation upon lapse in local 
immunosurveillance.
EBVMCU has been reported to arise in the setting of 
iatrogenic immunosuppression (56  %), primary immu-
nodeficiency (4  %), and advanced age (40  %), and is not 
typically associated with EBV viremia. Local diminu-
tion of EBV immunosurveillance as a result of primary 
or secondary immunosuppression and age-associated 
immunosenescence is thought to promote EBV-driven 
lymphoproliferation, clonal lymphocyte expansion, and 
lymphocyte transformation. Interestingly, in most of 
the cases of iatrogenic immunosuppression-associated 
EBVMCU, patients were also of advanced age (median 
63 years, mode 80 years, range 18–81 years old) suggest-
ing that age-associated immunosenescence is a potent 
risk factor for development of EBVMCU. Patients with 
primary immunodeficiency-associated EBVMCU were of 
younger age (45–61 years). Although forming generaliza-
tions from two patients is problematic, the younger age of 
onset in these patients may reflect a more profound defi-
cit in immunosurveillance. Interestingly, 62  % of the 52 
Fig. 4 a Left sided facial swelling causing lip droop and associated drooling. b , c Left palatal EBVMCU with associated maxillary teeth loss. d 
EBVMCU along right upper inner gum line extending from incisors to molars. e Hypertrophy of right upper gum line
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patients with known EBVMCU have been women, includ-
ing 62 % of the patients with iatrogenic immunosuppres-
sion-associated EBVMCU, 100  % of the patients with 
primary immunodeficiency EBVMCU, and 55  % of the 
patients with immunosenescence-associated EBVMCU. 
The significance of this observation is unclear, as there 
is not a strong gender bias among other EBV-associated 
lymphoproliferative disorders with the exception of a 
male predominance in Burkitt lymphoma and the mixed 
cellularity subtype of classic Hodgkin lymphoma [57].
EBVMCU has generally been referred to as an indo-
lent, self-limited disease with a benign clinical course that 
Fig. 5 Hematoxylin and eosin (H&E) stain of left palatal ulcer demonstrating a heterogeneous admixture of large atypical lymphocytes with occa-
sional Hodgkin Reed-Sternberg (HRS) morphology, small lymphocytes, and histiocytes. HRS cells express CD30, PAX5, and EBER1 consistent with 
EBV-infected B-lymphocytes
Fig. 6 Axial and sagittal views of radiotherapy plan
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often does not require treatment. Of the patients with iat-
rogenic immunosuppressant-associated EBVMCU, 68  % 
experienced complete clinical remission with reduction 
in immunosuppression alone. Three patients required 
rituximab in addition to immunosuppression (12 %), one 
patient underwent surgical excision of their lesion in 
addition to immunosuppression (4  %), and one patient 
received aggressive treatment with R-CHOP chemother-
apy (rituximab, cyclophosphamide, doxorubicin, vincris-
tine, prednisone), all with complete clinical responses. 
Two patients died shortly after diagnosis and one patient 
experienced disease progression despite reduction in 
immunosuppression, although this individual was receiv-
ing dual antimetabolite and anti-TNFα therapy. Taken 
together, these outcomes suggest that EBVMCU second-
ary to iatrogenic immunosuppression responds very well 
to reduction in immunosuppression. Rituximab, a mono-
clonal antibody against CD20 that results in selective lym-
phodepletion of B-cells, may provide additional benefit by 
significantly reducing the local clonal B-cell proliferative 
response to EBV in EBVMCU. However, given aggres-
sive therapy with R-CHOP was only employed in 1 case, 
high intensity B-cell directed immunochemotherapy may 
not be routinely necessary to achieve complete clinical 
response in EBVMCU secondary to iatrogenic immu-
nosuppression. These treatment strategies are similar to 
the management approach in PTLD where reduction in 
immunosuppression [58] with or without rituximab [59], 
surgical excision of local disease [60], and CHOP [61] 
have demonstrated overall excellent response rates.
Among the patients with age-associated immunose-
nescence, 59  % did not receive treatment, of which six 
experienced spontaneous remissions without interven-
tion (35 %), three experienced a relapsing-remitting dis-
ease course (18 %) and one demonstrated prolonged, but 
stable disease (6  %). Seven patients required treatment 
(41  %), of whom one underwent surgical resection, 
three received radiation therapy, two received R-CHOP, 
and one received R-CHOP +  radiation therapy, all with 
complete clinical responses. Collectively, only 37.5  % of 
patients in this older population demonstrated a benign 
clinical course. These outcomes suggest that EBVMCU 
associated with age-related immunosenescence responds 
to treatment with radiation therapy or R-CHOP and 
is associated with sustained disease response. Sponta-
neous disease remission has been observed in six of 10 
untreated cases, however with this small number of 
patients it is difficult to conclude that age-associated 
EBVMCU has a high likelihood of spontaneous remis-
sion without treatment.
Two cases of EBVMCU occurring in individuals with 
primary immune deficiency have been published, and in 
both cases individuals required treatment. One patient 
had a deficiency of cell-mediated immunity, while the 
other had a defect in humoral immunity. The patient 
with a primary T-cell deficiency had severely depressed 
CD4 T-cell (76  L/μL, reference range 354–1526  L/μL) 
and CD8 T-cell (71  L/μL, reference range 318–1458  L/
μL) counts in the setting of systemic lupus erythematosus 
that had not required treatment for 10 years [62]. She had 
quantitatively normal B-cell and natural killer cell counts, 
and was found to have a mosaic X chromosome abnor-
mality (46,XX,delXq27; 46,XX). Quantitative immu-
noglobulin testing was not reported. Treatment with 8 
doses of rituximab (375  mg/m2) resulted in complete 
clinical remission of her EBVMCU despite persistence of 
her T-cell deficiency.
The patient with primary hypogammaglobulinemia 
had normal quantitative lymphocyte counts and periph-
eral blood lymphocyte phenotyping by flow cytometry, 
however had markedly reduced IgG (351  mg/dL, refer-
ence range 700–1600 mg/dL), IgM (26 mg/dL, reference 
range 40–230 mg/dL), and IgA (9 mg/dL, reference rage 
70–400 mg/dL) levels in the setting of a history of type 
1 diabetes mellitus and recurrent infections since young 
adulthood [63]. She was treated with 4 weekly doses of 
rituximab (375 mg/m2) and monthly intravenous immu-
noglobulin infusions (600 mg/kg) and experienced symp-
tom improvement. Unfortunately her symptoms returned 
within 3 weeks of completing rituximab therapy and she 
experienced disease progression despite the addition 
of brentuximab vedotin (three doses at 1.8 mg/kg every 
3  weeks), an antibody–drug conjugate that delivers a 
microtubule-directed antineoplastic agent to CD30-
positive cells and has been FDA-approved for relapsed 
Hodgkin lymphoma [64] and has been successfully used 
to treat PTLD [65]. The authors indicated that they were 
exploring potential donor-derived EBV-specific T-lym-
phocyte treatment for this patient.
Fig. 7 Post-radiation treatment response with resolution of the 
ulcers along right inner gingiva and left palate. Facial swelling has 
also resolved
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Both cell-mediated immunity and humoral immunity 
are required to control EBV-driven lymphoproliferation, 
and deficiency in cytotoxic CD8 T-cell function, effector 
CD4 T-cell function, or in immunostimulatory gamma-
globulin production enables EBV persistence (reviewed 
in [66]). It is interesting that in both of these cases of 
primary immunodeficiency-associated EBVMCU, indi-
viduals had an underlying autoimmune disorder. Primary 
immunodeficiency has an established association with 
autoimmune disorders [67], including systemic lupus 
erythematosus [68] and type I diabetes mellitus [69], as 
well as lymphoproliferative disorders [70]. However, it 
is unclear whether a causal relationship exists between 
immunodeficiency and autoimmunity in these two 
individuals.
We question whether our patient may have an occult 
T-cell deficiency of unclear etiology given her signifi-
cantly reduced CD4 T-cell and moderately reduced CD8 
T-cell counts. Unfortunately further evaluation of immu-
nodeficiency in our patient is not currently possible as 
she is homeless, without contact information, and has 
not returned for medical monitoring or care. Our patient 
experienced an initial, but short-lived clinical response 
after rituximab monotherapy. This was followed by sig-
nificant disease progression over 2 years that was refrac-
tory to second rituximab challenge, however responded 
to 30  Gy fractionated external beam radiation therapy 
that has been maintained for 6  months, with long-term 
follow-up currently not available. Importantly, during 
the nearly 4-year duration of her disease, our patient 
experienced substantial pain, debilitation, disability, and 
malnutrition. Although limited to two case reports and 
potentially our patient, the overall clinical course of pri-
mary immunodeficiency-associated EBVMCU disease 
appears to be more aggressive, multifocal (66  %), with 
an earlier age of disease onset, and a requirement for 
directed therapy (rituximab) that may require treatment 
escalation (brentuximab vedotin, radiation therapy).
Additional treatment strategies that directly target EBV 
have been explored in other EBV-associated lymphopro-
liferative disorders. For example, antiviral therapy which 
targets EBV-specific thymidine kinase has been generally 
ineffective at controlling EBV-driven B-cell proliferation 
during viral latency, as it has no effect on EBV episomal 
DNA and only affects EBV-infected cells in lytic phase 
in which viral DNA is linearized [71]. Adoptive transfer 
of EBV-specific cytotoxic T-cells (EBV-CTLs) to recon-
stitute immunity to EBV has also been investigated. 
Both autologous and fully or partially human leukocyte 
antigen-matched allogeneic CTLs have been engineered 
ex  vivo to recognize latent EBV antigens. This strategy 
has been effective in the treatment of PTLD [72, 73] and 
classic Hodgkin lymphoma [74], however the cost and 
time required generating EBV-CTLs is currently a sig-
nificant limitation to the use and expansion of this tech-
nology. It is unclear if these treatment strategies will be 
effective in cases of progressive and treatment-refractory 
cases of EBVMCU such as the case reported by Kleinman 
[63].
All together, these 52 cases suggest that EBVMCU can 
be a benign and self-limiting condition in some, however 
at least 29 % require aggressive treatment with CD20- or 
CD30-directed antibody therapy, local radiation ther-
apy, local surgical excision, systemic chemotherapy, or a 
combination of these modalities, with an anticipation of 
durable complete remissions in most. Without aggres-
sive treatment, 16  % of patients reported to date have 
experienced persistent disease, a relapsing-remitting 
course, disease progression, or death, while two patients 
have experienced disease progression despite antibody-
directed therapy. Evaluation of all known case reports of 
EBVMCU including our patient experience suggests that 
EBVMCU can have a heterogeneous disease presenta-
tion, with self-resolving disease in some, but persistent 
and progressive disease in others requiring aggressive 
local or systemic therapy. Certainly the morbidity experi-
enced by our patient was sobering.
Conclusions
In summary, EBVMCU is a rare EBV-associated lym-
phoproliferative disorder that is likely under reported 
secondary to its recent recognition and morphologic 
and immunophenotypic similarities to Hodgkin lym-
phoma and diffuse large B cell lymphoma. Therefore, 
we suggest consideration of its inclusion in the next 
iteration of the WHO classification of lymphoprolifera-
tive disorders. This disease is characterized by solitary 
or multifocal ulcers of the oropharynx, gastrointestinal 
tract, and skin that result from EBV-driven proliferation 
of B- and T-lymphocytes in the setting of local lapse in 
immunosurveillance secondary to iatrogenic immuno-
suppression, primary immunodeficiency, or age-related 
immunosenescence. The disease course is heterogeneous, 
with some patients experiencing spontaneous remissions 
or complete clinical response to reduction in their immu-
nosuppressive therapies. However for others, EBVMCU 
can be a persistent, debilitating disease that requires 
aggressive therapy with CD20- or CD30-directed anti-
body therapy, local radiation therapy, local surgical exci-
sion, systemic chemotherapy, or a combination of these 
therapies. Disease response to local or systemic therapy is 
generally excellent (93 %) and sustained (reported dura-
bility on follow-up from 3 to 111 months). The care of the 
patient with EBVMCU is complex. Treatment decisions 
are not evidence-based and no expert opinion exists. 
Therefore, we have summarized the limited published 
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experiences with EBVMCU disease to provide a frame-
work from which to guide management.
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